DEFA14A: Jupiter Neurosciences Corrects Proxy Statement Share Cap

Jupiter Neurosciences, Inc. filed a supplement to its definitive proxy statement to correct scriveners' errors regarding the maximum number of shares issuable under its Standby Equity Purchase Agreement and Convertible Notes.

Summary

• The supplement amends the definitive proxy statement filed on November 6, 2025, for the Annual Meeting of Stockholders to be held on December 19, 2025.
• The primary purpose is to correct certain calculations in the Proxy Statement due to a scriveners' error.
• The maximum number of shares of common stock issuable to Yorkville under the Standby Equity Purchase Agreement (SEPA) and upon conversion of Convertible Notes (the Exchange Cap) is corrected from 6,638,088 shares to 6,855,459 shares.
• This corrected Exchange Cap represents 19.99% of the shares of common stock outstanding immediately prior to the execution of the SEPA.
• The Company will seek requisite stockholder approval at the December 19, 2025 Annual Meeting to issue shares in excess of this 6,855,459 share Exchange Cap.
• If stockholder approval is obtained, the Company would be able to issue shares necessary to obtain the entire $20.0 million aggregate purchase commitment from Yorkville under the SEPA and convert all outstanding Convertible Notes without further aggregate share issuance limitations under Nasdaq rules.
• The applicable Minimum Price for Nasdaq Listing Rule 5635(d) is $1.48 per share, based on the SEPA signing on October 24, 2025.
• The percentage of issued and outstanding shares at the time of SEPA execution, if the First Convertible Note converts at its absolute Floor Price of $0.296, is corrected from 40.7% to 39.3% (representing 13,513,514 shares).
• The percentage of issued and outstanding shares at the time of SEPA execution, if the Second Convertible Note converts at its absolute Floor Price of $0.296, is corrected from 20.3% to 19.7% (representing 6,756,757 shares).

Sentiment

Score: 6

Explanation: The filing corrects previous errors, which is a positive for transparency and accuracy. However, the underlying financing mechanisms (SEPA, Convertible Notes) and the potential for significant dilution at floor prices, while not new, are reiterated with corrected figures, which could be viewed with caution by investors. The need for stockholder approval for full financing access introduces a minor uncertainty.

Positives

• The correction of scriveners' errors enhances the accuracy and transparency of the Company's disclosures to stockholders.
• Clarified share issuance limits provide more precise information for investor decision-making regarding potential dilution.

Negatives

• The initial errors in the definitive proxy statement required a subsequent supplement, potentially indicating an oversight in the original filing process.

Risks

• Failure to obtain requisite stockholder approval at the Annual Meeting will limit the Company's ability to issue shares in excess of the 6,855,459 share Exchange Cap to Yorkville under the SEPA and upon conversion of the Convertible Notes.
• If stockholder approval is not secured, the Company may not be able to obtain the entire $20.0 million aggregate purchase commitment from Yorkville.
• Potential for significant dilution exists if convertible notes are converted at the absolute Floor Price of $0.296, leading to 13,513,514 shares for the First Convertible Note (39.3% of outstanding shares at SEPA execution) and 6,756,757 shares for the Second Convertible Note (19.7% of outstanding shares at SEPA execution).

Future Outlook

The Company plans to seek stockholder approval at the upcoming Annual Meeting on December 19, 2025, to issue shares in excess of the Nasdaq Exchange Cap to Yorkville under the SEPA and upon conversion of the Convertible Notes. If approved, this would allow the Company to access the full $20.0 million aggregate purchase commitment and facilitate full conversion of outstanding Convertible Notes without further share issuance limitations under Nasdaq rules.

Industry Context

This filing primarily addresses specific corporate financing and governance matters related to a single company's compliance with Nasdaq listing rules for equity issuances. It does not directly reflect broader industry trends, though the use of SEPA and convertible notes is a common financing mechanism for growth-stage companies, particularly in the biotechnology or neuroscience sectors, to secure capital.

Corporate Governance

Related Party Transactions

• The filing details transactions with Yorkville (YA II PN, Ltd.) under a Standby Equity Purchase Agreement (SEPA) and Convertible Notes. Yorkville is a counterparty to these financing instruments.

Stakeholder Impact

• Shareholders are directly impacted by the vote on Proposal No. 5, which determines the extent of potential future dilution from share issuances under the SEPA and Convertible Notes. The corrected figures provide more accurate information for their voting decision.
• Creditors (Yorkville) will have their ability to convert Convertible Notes and provide further advances under the SEPA contingent on stockholder approval, affecting their investment terms and liquidity.

Next Steps

• The Company will seek requisite stockholder approval at the Annual Meeting on December 19, 2025, for Proposal No. 5.
• If approved, the Company will be able to issue and sell shares to Yorkville under the SEPA and upon conversion of Convertible Notes without further aggregate share issuance limitations under Nasdaq rules.

Key Dates

Keywords

Jupiter Neurosciences, SEC filing, DEFA14A, proxy statement, stockholder meeting, share cap, Exchange Cap, Nasdaq rules, SEPA, Standby Equity Purchase Agreement, Convertible Notes, Yorkville, share issuance, dilution, corporate governance, financial reporting, JUPN